Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

IDeAS Probiotic Pilot (IDeAS)

9. November 2026 aktualisiert von: Stephanie A. Fritz, Washington University School of Medicine

Investigating Staphylococcus Aureus Colonization Dynamics in the Context of Bacillus Probiotic

Infections caused by Staphylococcus aureus pose a major public health threat, and existing prevention methods are burdensome to patients and provide only limited benefit. In this collaborative study, participants will trial a probiotic intervention and share their perspectives regarding study design and feasibility. The goal of this study is to characterize colonization kinetics of S. aureus and B. subtilis in the nares, skin, and stool before, during, and after administration of a nutritional supplement probiotic blend. We will establish the S. aureus intestinal colonization kinetics over a 3-month Natural History Phase, followed by a 1-month administration of the probiotic (Intervention Phase), and a 3-month Post-Intervention Observational Phase. Samples from the nares, skin, and stool will be collected at each of the 10 study visits to detect S. aureus and B. subtilis. We will also conduct interviews to assess acceptability, appropriateness, and feasibility of the probiotic and study regimen.

Studienübersicht

Detaillierte Beschreibung

The ongoing epidemic of Staphylococcus aureus skin and soft tissue infections in healthy individuals is a significant public health burden. S. aureus colonization (having the germ living in or on the body without symptoms) poses risk for developing symptomatic S. aureus infections. Thus, topical antimicrobials and antiseptics are often used to eliminate or reduce the burden of S. aureus from the nose and skin (known as decolonization). While current decolonization practices with topical antimicrobials effectively eliminate S. aureus carriage and prevent recurrent infections in the immediate period, their effectiveness wanes over time. While the nose has traditionally been considered the primary reservoir of S. aureus carriage, the intestine is also an important, yet under-appreciated, reservoir of S. aureus. Intestinal colonization can lead to persistent S. aureus colonization at other body sites despite topical antimicrobial decolonization.

Probiotics can promote a healthy gut microbiome by increasing the presence of beneficial bacteria and reducing the presence of pathogens, thereby improving digestive health and enhancing immune function. Bacillus subtilis is a benign microorganism that has been shown to inhibit S. aureus from colonizing the intestine. In a trial conducted in rural Thailand, daily oral administration of B. subtilis MB40 significantly reduced S. aureus in stool and nasal samples, without adverse effects. Bacillus coagulans has been demonstrated to decrease gastrointestinal symptoms, without adverse effects. B. subtilis and B. coagulans are both included as supplements in foods and available in pill form. In this investigation, we will study a probiotic blend of B. subtilis and B. coagulans, which is commercially available as a nutritional supplement, Ameo LifeTM Digest Probiotic. The goals of this study are to 1) establish the longitudinal colonization kinetics of S. aureus and B. subtilis before, during, and after probiotic administration; 2) assess the tolerability and delivery fidelity of the probiotic administration; and 3) engage participant perspectives to optimize study procedures and develop an intervention that is acceptable, appropriate, feasible, and likely to be adopted in real-world settings.

In this study, 20 healthy adults who are at risk for S. aureus infection who are colonized with S. aureus will be enrolled. S. aureus-colonized participants will be followed during a 3-month Natural History Phase, followed by a 1-month administration of the probiotic, and finally, a 3-month Post-Intervention Observational Phase. Stool, nasal, and skin samples will be collected 10 times over 7 months to quantify S. aureus and B. subtilis longitudinally. Participant acceptability and appropriateness will be assessed through brief, semi-structured interviews at the end of the probiotic administration and the conclusion of the Post-Intervention Observational Phase.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

20

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Stephanie Fritz, MD, MSCI
  • Telefonnummer: (314) 454-4114
  • E-Mail: Fritz.s@wustl.edu

Studieren Sie die Kontaktsicherung

  • Name: Mary Boyle, RN, MSN
  • Telefonnummer: 3(14) 286-1207
  • E-Mail: mboyle@wustl.edu

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Participants meeting eligibility criteria who provide written informed consent. Participants will be recruited from a pre-existing participant pool developed through prior studies conducted by our research team. Participants will be from St. Louis, Missouri and surrounding areas.

Beschreibung

Inclusion Criteria

  1. Colonized with S. aureus in anterior nares, inguinal folds, or stool
  2. Age ≥ 18 years
  3. Able to complete the informed consent process
  4. Willing and able to complete the study protocol, study-related activities, and visits

Exclusion Criteria

  1. Pregnant or planning to become pregnant in the next 9 months
  2. Breastfeeding
  3. Abnormalities of the gastrointestinal tract (e.g., inflammatory bowel disease, ulcers, celiac diseases, etc.)
  4. Immunodeficiency
  5. Use of any antibiotics or probiotics outside of the study within 90 days of study screening
  6. Any contraindication to taking probiotics
  7. No permanent home, or living in a group home/ long term care facility

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Characterize S. aureus in the stool from the pre-intervention sampling to the Week 4 sampling (completion of the Intervention Phase)
Zeitfenster: Start of the pre-intervention phase and end of the intervention phase

Compare change in S. aureus log10 S. aureus CFU/g count in stool from the pre-intervention sampling to the week-4 (end-of-dosing) sampling.

Start of the pre-intervention phase and end of the intervention phase
Evaluate the implementation outcomes of acceptability, appropriateness, and feasibility of the study procedures from the participant's perspective.
Zeitfenster: End of the intervention phase and end of the post-intervention phase

Create a participant-informed account of what makes the regimen acceptable and appropriate, benchmarked feasibility data against pre-specified go/no-go thresholds, and a prioritized set of protocol refinements. Comparing facilitators and barriers at the end-of-intervention visit versus the end-of-follow-up visit will indicate whether acceptability changes over time, and benchmarks falling below the thresholds will pinpoint where recruitment, retention, or scheduling procedures require modification.

End of the intervention phase and end of the post-intervention phase

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
S. aureus nares pre-intervention to week-4 (end-of-dosing) sampling.
Zeitfenster: Pre-intervention to week-4 sampling

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-4 (end-of-dosing) sampling.

Pre-intervention to week-4 sampling
S. aureus nares pre-intervention to week-6 sampling.
Zeitfenster: Pre-intervention to week-6 sampling

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-6 sampling.

Pre-intervention to week-6 sampling
S. aureus nares pre-intervention to month 2 sampling.
Zeitfenster: Pre-intervention sampling to month 2 sampling.

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 2 sampling.

Pre-intervention sampling to month 2 sampling.
S. aureus nares pre-intervention to month 3 sampling.
Zeitfenster: Pre-intervention sampling to month 3 sampling.

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 3 sampling.

Pre-intervention sampling to month 3 sampling.
S. aureus nares pre-intervention to month 4 sampling.
Zeitfenster: Pre-intervention to month 4 sampling.

Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 4 sampling.

Pre-intervention to month 4 sampling.
S. aureus inguinal fold pre-intervention to week-4 (end-of-dosing) sampling.
Zeitfenster: Pre-intervention to week-4 sampling

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-4 (end-of-dosing) sampling.

Pre-intervention to week-4 sampling
S. aureus inguinal fold pre-intervention to week-6 sampling.
Zeitfenster: Pre-intervention to week-6 sampling

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-6 sampling.

Pre-intervention to week-6 sampling
S. aureus inguinal fold pre-intervention to month 2 sampling.
Zeitfenster: Pre-intervention sampling to month 2 sampling.

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 2 sampling.

Pre-intervention sampling to month 2 sampling.
S. aureus inguinal fold pre-intervention to month 3 sampling.
Zeitfenster: Pre-intervention sampling to month 3 sampling.

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 3 sampling.

Pre-intervention sampling to month 3 sampling.
S. aureus inguinal fold pre-intervention to month 4 sampling.
Zeitfenster: Pre-intervention sampling to month 4 sampling.

Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 4 sampling.

Pre-intervention sampling to month 4 sampling.
Bacillus stool pre-intervention
Zeitfenster: Pre-intervention sampling

log10 B. subtilis CFU count at pre-intervention sampling

Pre-intervention sampling
Bacillus stool week-2 sampling
Zeitfenster: Week-2 sampling

log10 B. subtilis CFU count at week-2 sampling

Week-2 sampling
Bacillus stool week-4 sampling
Zeitfenster: Week-4 sampling

log10 B. subtilis CFU count at week-4 sampling

Week-4 sampling
Bacillus stool week-6 sampling
Zeitfenster: Week-6 sampling

log10 B. subtilis CFU count at week-6 sampling

Week-6 sampling
Bacillus stool month 2 sampling
Zeitfenster: Month 2 sampling

log10 B. subtilis CFU count at month 2 sampling

Month 2 sampling
Bacillus stool month 3 sampling
Zeitfenster: Month 3 sampling

log10 B. subtilis CFU count at month 3 sampling

Month 3 sampling
Bacillus stool month 4 sampling
Zeitfenster: Month 4 sampling

log10 B. subtilis CFU count at month 4 sampling

Month 4 sampling

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Stephanie A Fritz, MD, MSCI, Washington University School of Medicine

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. November 2026

Primärer Abschluss (Geschätzt)

1. November 2030

Studienabschluss (Geschätzt)

1. November 2031

Studienanmeldedaten

Zuerst eingereicht

9. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. November 2026

Zuerst gepostet (Tatsächlich)

16. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren